Most Popular
- UK fighters escort Pakistan plane to airport; two arrested
- Niko finds significant gas in India block; shares soar
- Video shows British police shooting soldier's suspected killers
- AirAsia still wants jets after record orders
- One Direction sweeps awards for most popular social media stars
- Psy imposter caught living the high life at Cannes film festival
- India passes law to stop sexual harassment at work
- Taliban attack international compound in Afghan capital
- Magnitude 8.2 earthquake strikes Russian Far East
- Jet Airways, SpiceJet report quarterly losses
Most Shared
- Qatar drops bid to move civil aviation body ICAO from Montreal
- New book asks: Could Germany have a Jewish chancellor?
- Napoli chief denies announcing Benitez capture
- Wockhardt hit by FDA import alert on drug plant
- Trade ministry recommends suspension of gold jewellery imports from Thailand
- AirAsia still wants jets after record orders
- Taliban attack international compound in Afghan capital
- Top generic drugmakers look to US as patents end
- Government to pay state-run fuel retailers $8.1 billion in Q4 oil subsidy
- ITV News Twitter account hacked by Syrian Electronic Army
Slow approvals put India's drug trials industry at risk
Comments (0)
Be the first to comment on reuters.com
Add yours using the box below.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
